Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia
暂无分享,去创建一个
Jeffrey A Lieberman | Patrick F Sullivan | Robert E Vann | Daniel E. Adkins | Diana O Perkins | J. Lieberman | P. Sullivan | J. Bukszár | J. McClay | T. Stroup | J. McEvoy | D. Perkins | R. Keefe | E. Oord | Amit N. Khachane | Patrick F. Sullivan | D. Adkins | R. Vann | Joseph L McClay | Jozsef Bukszár | Joseph P McEvoy | T Scott Stroup | Richard S E Keefe | Karolina Åberg | K. Åberg | Daniel E Adkins | Amit N Khachane | P. Beardsley | Patrick M Beardsley | Edwin J C G van den Oord | J. Mcevoy
[1] József Bukszár,et al. Estimating the posterior probability that genome-wide association findings are true or false , 2009, Bioinform..
[2] T. Lehtimäki,et al. Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach , 2007, BMC psychiatry.
[3] S. Kapur,et al. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. , 1999, The American journal of psychiatry.
[4] D. Zaykin,et al. Using the false discovery rate approach in the genetic dissection of complex traits: a response to Weller et al. , 2000, Genetics.
[5] Eden R Martin,et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. , 2009, American journal of human genetics.
[6] U Hegerl,et al. Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. , 2001, The American journal of psychiatry.
[7] A. Roses. Pharmacogenetics and the practice of medicine , 2000, Nature.
[8] J. Lieberman,et al. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response , 2007, Journal of psychopharmacology.
[9] Steven G Potkin,et al. Pharmacogenomics in schizophrenia: the quest for individualized therapy. , 2002, Human molecular genetics.
[10] J. Lieberman,et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1 , 2009, Molecular Psychiatry.
[11] S. Levy,et al. Genome-Wide Association Analyses Identify SPOCK as a Key Novel Gene Underlying Age at Menarche , 2009, PLoS genetics.
[12] Robert K. Heaton,et al. Wisconsin Card Sorting Test Manual – Revised and Expanded , 1993 .
[13] S. Muallem,et al. SLC26A9 is a Cl− channel regulated by the WNK kinases , 2007, The Journal of physiology.
[14] D. Sanger. The search for novel antipsychotics: pharmacological and molecular targets , 2004, Expert opinion on therapeutic targets.
[15] Xiangding Chen,et al. Genome-wide association scan for stature in Chinese: evidence for ethnic specific loci , 2009, Human Genetics.
[16] Patrick F Sullivan,et al. False discoveries and models for gene discovery. , 2003, Trends in genetics : TIG.
[17] J. Thierry-Mieg,et al. AceView: a comprehensive cDNA-supported gene and transcripts annotation , 2006, Genome Biology.
[18] S. Faraone,et al. Heterogeneity of schizophrenia: a study of individual neuropsychological profiles , 2004, Schizophrenia Research.
[19] Herbert Y Meltzer,et al. Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2008, Neuropsychopharmacology.
[20] D. Ge,et al. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis , 2009, European Journal of Human Genetics.
[21] J. Lieberman,et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. , 2003, Schizophrenia bulletin.
[22] Larry J. Seidman,et al. NEUROCOGNITION IN FIRST-EPISODE SCHIZOPHRENIA: A META-ANALYTIC REVIEW , 2010, Schizophrenia Research.
[23] Michael Williams. Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia. , 2003, Current opinion in investigational drugs.
[24] Michael F. Green,et al. What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.
[25] Karl J. Friston,et al. Variance Components , 2003 .
[26] P. Gorwood,et al. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia , 2008, European Neuropsychopharmacology.
[27] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] H. Meltzer,et al. Dr. Meltzer and Mr. Cola Reply , 1995 .
[29] G. Giebisch,et al. Paracellular Cl- permeability is regulated by WNK4 kinase: insight into normal physiology and hypertension. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[30] John D. Storey. The positive false discovery rate: a Bayesian interpretation and the q-value , 2003 .
[31] D. Wechsler. WAIS-R manual : Wechsler adult intelligence scale-revised , 1981 .
[32] J. Simonoff,et al. Procedures for the Identification of Multiple Outliers in Linear Models , 1993 .
[33] D. Wechsler. Wechsler Intelligence Scale for Children , 2020, Definitions.
[34] C. Correll,et al. PAGES_DCNS 46_5.qxd:DCNS#45 , 2010 .
[35] Daniel E. Adkins,et al. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE , 2009, Schizophrenia Research.
[36] M. First,et al. Structured clinical interview for DSM-IV axis I disorders : SCID-I: clinical version : administration booklet , 1996 .
[37] B W Brown,et al. Methods of correcting for multiple testing: operating characteristics. , 1997, Statistics in medicine.
[38] M. Daly,et al. Genetic Mapping in Human Disease , 2008, Science.
[39] Michael F. Green,et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. , 2003, Schizophrenia bulletin.
[40] S. Hyman,et al. What Are the Right Targets for Psychopharmacology? , 2003, Science.
[41] P. Zandi,et al. The promise and reality of pharmacogenetics in psychiatry. , 2010, Clinics in laboratory medicine.
[42] T. Libermann,et al. ESE-3, a Novel Member of an Epithelium-specific Ets Transcription Factor Subfamily, Demonstrates Different Target Gene Specificity from ESE-1* , 2000, The Journal of Biological Chemistry.
[43] R. Kerwin,et al. Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[44] J Blangero,et al. Large upward bias in estimation of locus-specific effects from genomewide scans. , 2001, American journal of human genetics.
[45] C. Spencer,et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up , 2008, Nature Genetics.
[46] John G. Gray,et al. Medicine , 1902, Glasgow Medical Journal.
[47] G. He,et al. Intersectin links WNK kinases to endocytosis of ROMK1. , 2007, The Journal of clinical investigation.
[48] J. Ioannidis,et al. Replication validity of genetic association studies , 2001, Nature Genetics.
[49] A. Mushegian,et al. The Epithelium-specific ETS Protein EHF/ESE-3 Is a Context-dependent Transcriptional Repressor Downstream of MAPK Signaling Cascades* , 2001, The Journal of Biological Chemistry.
[50] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[51] N. Risch,et al. The continuous performance test, identical pairs version (CPT-IP): I. new findings about sustained attention in normal families , 1988, Psychiatry Research.
[52] S. Tsukita,et al. Pores in the Wall , 2000, The Journal of cell biology.
[53] T. Goldberg,et al. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. , 1997, Archives of general psychiatry.
[54] Gregory D. Schuler,et al. Database resources of the National Center for Biotechnology , 2003, Nucleic Acids Res..
[55] G. Jenkins,et al. A Genomewide Association Study of Citalopram Response in Major Depressive Disorder , 2010, Biological Psychiatry.
[56] Jianxin Shi,et al. Common variants on chromosome 6p22.1 are associated with schizophrenia , 2009, Nature.
[57] J Licinio,et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.
[58] J. Lieberman,et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. , 2007, The American journal of psychiatry.
[59] M. A. Black,et al. A note on the adaptive control of false discovery rates , 2004 .
[60] John A Sweeney,et al. Neurocognitive allied phenotypes for schizophrenia and bipolar disorder. , 2007, Schizophrenia bulletin.
[61] W. Banks,et al. Intravenous human interleukin-1alpha impairs memory processing in mice: dependence on blood-brain barrier transport into posterior division of the septum. , 2001, The Journal of pharmacology and experimental therapeutics.
[62] Michael F. Green,et al. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. , 2007, Archives of general psychiatry.
[63] John D. Storey,et al. Empirical Bayes Analysis of a Microarray Experiment , 2001 .
[64] V. Carey,et al. Mixed-Effects Models in S and S-Plus , 2001 .
[65] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[66] S. Hyman,et al. Medicine. What are the right targets for psychopharmacology? , 2003, Science.
[67] Todd Lencz,et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? , 2007, Archives of general psychiatry.
[68] M. Arranz,et al. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research , 2007, Molecular Psychiatry.
[69] M. Shapero,et al. DMET microarray technology for pharmacogenomics-based personalized medicine. , 2010, Methods in molecular biology.
[70] Vladimir I. Vladimirov,et al. Genomewide Pharmacogenomic Analysis of Response to Treatment with Antipsychotics , 2009, Molecular Psychiatry.
[71] J. Brandt. The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms. , 1991 .
[72] D. Bates,et al. Mixed-Effects Models in S and S-PLUS , 2001 .
[73] T. Hershey,et al. Short- and Long-Term Spatial Delayed Response Performance Across the Lifespan , 2004, Developmental neuropsychology.
[74] F. Borgèse,et al. Characterization of SLC26A9, Facilitation of Cl- Transport by Bicarbonate , 2008, Cellular Physiology and Biochemistry.
[75] P. Sullivan,et al. Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in Schizophrenia , 2008, Biological Psychiatry.
[76] H. Meltzer,et al. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. , 1995, The American journal of psychiatry.
[77] Michael F. Green,et al. Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial , 2006, Neuropsychopharmacology.
[78] M. Leboyer,et al. Pharmacogenetic study of atypical antipsychotic drug response: Involvement of the norepinephrine transporter gene , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[79] Anil K Malhotra,et al. Pharmacogenetics of psychotropic drug response. , 2004, The American journal of psychiatry.
[80] S. Grant,et al. Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins , 2009, Molecular systems biology.
[81] E. Dietzsch,et al. Identification of a new family of human epithelial protein kinases containing two leucine/isoleucine-zipper domains. , 1993, European journal of biochemistry.
[82] J. Lieberman,et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.
[83] H. Goldstein. Multilevel Statistical Models , 2006 .
[84] Michael F. Green,et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.